# Verification Summary — Spec 016 echelon-proto Reverse Engineering

**Run ID**: build-1775167332
**Date**: 2026-04-03
**Verdict**: PASS
**Coverage**: 38/38 ACs (100%)
**Contradiction scan**: 0 hard, 1 soft advisory (C-005/C-006, 37-42% vs 40-60% estimate — advisory only)

---

## REQ-by-REQ Verdict

| REQ | Description | ACs | Verdict |
|-----|-------------|-----|---------|
| REQ-RE-001 | Architecture Map | 6 | **PASS** |
| REQ-RE-002 | Novelty Catalogue | 10 | **PASS** |
| REQ-RE-003 | Patent Defensibility Analysis | 8 | **PASS** |
| REQ-RE-004 | Inter-Process Effectiveness | 10 | **PASS** |
| REQ-RE-005 | Evidence Compilation | 8 | **PASS** |

---

## Key Evidence Verified

- **AC-001-001**: `agent-architecture.md` — 42-agent structured table, tier/codename/artifact per row, count verified by file scan
- **AC-001-003**: `agent-architecture.md` + `evidence-package.md` — 30 state.json fields with type/purpose/writer/readers
- **AC-002-010**: `novelty-catalogue-final.md` Section on NOVEL-004 — SPECULATION NOTICE block, P-005 cited, "DO NOT FILE" in IP matrix
- **AC-003-002**: `patent-analysis-final.md` Section 6 — NS-003 prosecution-ready claim language (A)-(D), AGM postulates named, confidence 0.5-0.95
- **AC-003-007**: All HIGH mechanisms include "Weakest Point" and "Obviousness Risk" (Graham v John Deere standard) analysis
- **AC-004-006**: `inter-process-effectiveness-final.md` — endocrine decay rates (adrenaline 0.6×, serotonin 0.95×), circuit breakers (±0.4, [0.0, 1.0]), propagation 30% dopamine
- **AC-005-001**: `evidence-package.md` — Grade A: arxiv:2510.09355 (NL2GenSym 86%+), arxiv:2603.17244 (Kumiho 93.3%)
- **AC-005-004**: `evidence-package.md` — U-015-002 cited (176 lines, 8 queries, zero prior literature for NS-003 combination)

---

## Constitution Compliance

| Principle | Status |
|-----------|--------|
| P-004: Every claim cites evidence | **VERIFIED** — all mechanism entries include file:line citations |
| P-005: NOVEL-004 = SPECULATION | **VERIFIED** — block notice in novelty-catalogue-final.md, evidence-package.md, patent-analysis-final.md |
| P-006: CA overlays GATE_BLOCKED | **VERIFIED** — NOVEL-010 block notice, no implementation code present |
| P-007: Pre-dispatch gates documented | **VERIFIED** — architecture-gaps.md Gap 2: PASS/CONSULT/DENY flow |

---

## Blocking Unknowns (Status at Build Complete)

| ID | Description | Status |
|----|-------------|--------|
| U-CA-004 | CA overlay gate experiment | OPEN — blocks 5 overlays |
| U-008 | NS-003 prototype not built | OPEN — FILE IMMEDIATELY prerequisite |
| U-003 | SAGE quality gate uncalibrated | OPEN — medium priority |
| U-005 | Endocrine efficacy unmeasured | OPEN — required for CLAIM-002 |

---

## Deliverable Index (Final)

| File | Phase | Status |
|------|-------|--------|
| `agent-architecture.md` | Assembly T-004 | FINAL |
| `novelty-catalogue-final.md` | Assembly T-005 | FINAL |
| `patent-analysis-final.md` | Assembly T-006 | FINAL |
| `inter-process-effectiveness-final.md` | Assembly T-007 | FINAL |
| `evidence-package.md` | Assembly T-008 | FINAL |
| `consolidation-report.md` | Foundation T-001 | FINAL |
| `integration-notes.md` | Foundation T-002 | FINAL |
| `spec015-verification.md` | Foundation T-003 | FINAL |

---

**BUILD_DONE. All gates passed. Spec 016 reverse engineering analysis complete.**
